Ziccum AB (publ) (‘Ziccum’) has received notification from CEPI (the Coalition for Epidemic Preparedness), that its joint Expression of Interest, submitted in partnership with an mRNA-focused biotech company in January 2023, has not been selected for the next stage of application work. In its notification, CEPI points Ziccum towards an upcoming 2023 Call for Proposals on vaccine manufacturing innovation that “may be a good fit with your technology” and “an opportunity for you to collaborate with CEPI in the future”.
Ziccum AB (publ) (‘Ziccum’) has received notification from the CEPI Secretariat, that its joint January 2023 Expression of Interest, submitted in partnership with an mRNA-focused biotech company, has not been selected for further development. In the CEPI notification, the Secretariat points Ziccum towards an upcoming 2023 Call for Proposals for Applications on vaccine manufacturing innovation including that it “may be a good fit with your technology” and “an opportunity for you to collaborate with CEPI in the future”.
After initially communicating that it would not submit a proposal, Ziccum did submit a first stage brief application, a so called Expression of Interest, to CEPI with a Biotech partner in January 2023, before the company’s recent announcement of a fully funded mRNA Feasibility Study with an international Biotech leader in mRNA development.
CEO Ann Gidner: “With the funding secured in our new Feasibility Study, plus the soft funding received from Eurostars in December for our 3D modelling project with the Zurich University of Applied Sciences, this current news does not significantly affect or change Ziccum’s current funding position. It does however potentially open up another door for us with CEPI, which we will consider carefully. We are very pleased to continue intensifying our present Partnering Pipeline with ongoing and new dialogues as part of our industrial and business development. We are focused firmly on promising options ahead for us and our unique drying technology.”